Dr. Carey on Treating Triple-Negative Breast Cancer
Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.
Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.
Carey says the main challenge in treating triple-negative breast cancer is that physicians are limited to chemotherapy outside of clinical trials. However, there are relatively low-toxicity chemotherapy regimens that are used in the treatment of these patients.
Triple-negative breast cancer tends to behave like other subsets where taxanes are effective, and it has been shown that platinum drugs are as effective as taxanes in the first-line setting, Carey says.
Even though treatment in the space is limited to chemotherapy, Carey says there are 4-5 agents that can be used for the treatment of triple-negative breast cancer.
<<<
View more from the 32nd Annual Miami Breast Cancer Conference
